Literature DB >> 12019134

Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa.

Samuel Bellais1, Olivier Mimoz, Sophie Léotard, Anne Jacolot, Olivier Petitjean, Patrice Nordmann.   

Abstract

A rat pneumonia model was established with a Pseudomonas aeruginosa strain that produced the plasmid-encoded metallocarbapenemase VIM-2. A significant decrease in lung bacterial titers was observed when imipenem, cefepime, ceftazidime, and piperacillin-tazobactam were given at the highest doses recommended for humans, despite their high MICs. Aztreonam at high doses produced a similar decrease in bacterial titers.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12019134      PMCID： PMC127240          DOI： 10.1128/AAC.46.6.2032-2034.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece.

Authors:  A Tsakris; S Pournaras; N Woodford; M F Palepou; G S Babini; J Douboyas; D M Livermore
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

2.  Carbapenem-hydrolysing VIM-2 metallo- beta-lactamase in Pseudomonas aeruginosa from Greece.

Authors:  A Mavroidi; A Tsakris; E Tzelepi; S Pournaras; V Loukova; L S Tzouvelekis
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

3.  Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the bla(VIM-2) carbapenem-hydrolyzing beta-lactamase gene and of two novel aminoglycoside resistance gene cassettes.

Authors:  L Poirel; T Lambert; S Türkoglü; E Ronco; J Gaillard; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China.

Authors:  P M Hawkey; J Xiong; H Ye; H Li; F H M'Zali
Journal:  FEMS Microbiol Lett       Date:  2001-01-01       Impact factor: 2.742

5.  Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model.

Authors:  E J Ernst; S Hashimoto; J Guglielmo; T Sawa; J F Pittet; H Kropp; J J Jackson; J P Wiener-Kronish
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 6.  Carbapenemases: a problem in waiting?

Authors:  D M Livermore; N Woodford
Journal:  Curr Opin Microbiol       Date:  2000-10       Impact factor: 7.934

7.  IMP-4, a novel metallo-beta-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998.

Authors:  Y W Chu; M Afzal-Shah; E T Houang; M I Palepou; D J Lyon; N Woodford; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.

Authors:  L Poirel; T Naas; D Nicolas; L Collet; S Bellais; J D Cavallo; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase.

Authors:  G Cornaglia; A Mazzariol; L Lauretti; G M Rossolini; R Fontana
Journal:  Clin Infect Dis       Date:  2000-11-06       Impact factor: 9.079

10.  Molecular heterogeneity of bla(VIM-2)-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-beta-lactamase.

Authors:  L Pallecchi; M L Riccio; J D Docquier; R Fontana; G M Rossolini
Journal:  FEMS Microbiol Lett       Date:  2001-02-20       Impact factor: 2.742
View more
  11 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States.

Authors:  K Lolans; A M Queenan; K Bush; A Sahud; J P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Metallo-beta-lactamase or extended-spectrum beta-lactamase: a wolf in sheep's clothing.

Authors:  Björn A Espedido; Lee C Thomas; Jonathan R Iredell
Journal:  J Clin Microbiol       Date:  2007-04-04       Impact factor: 5.948

Review 4.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

Review 5.  Metallo-beta-lactamases: the quiet before the storm?

Authors:  Timothy R Walsh; Mark A Toleman; Laurent Poirel; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

6.  Clonal diversity of metallo-beta-lactamase-possessing Pseudomonas aeruginosa in geographically diverse regions of Japan.

Authors:  Soichiro Kimura; Jimena Alba; Katsuaki Shiroto; Reiko Sano; Yoshihito Niki; Shigefumi Maesaki; Koji Akizawa; Mitsuo Kaku; Yuji Watanuki; Yoshikazu Ishii; Keizo Yamaguchi
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

7.  Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan.

Authors:  Hisaaki Nishio; Masaru Komatsu; Naohiro Shibata; Kouichi Shimakawa; Noriyuki Sueyoshi; Toshiro Ura; Kaori Satoh; Masahiro Toyokawa; Tatsuya Nakamura; Yasunao Wada; Tamaki Orita; Tomomi Kofuku; Katsutoshi Yamasaki; Masako Sakamoto; Shohiro Kinoshita; Masanori Aihara; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

8.  In vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosa.

Authors:  Shigeharu Oie; Yumi Fukui; Masaya Yamamoto; Yuki Masuda; Akira Kamiya
Journal:  BMC Infect Dis       Date:  2009-08-10       Impact factor: 3.090

9.  Extensively drug-resistant (XDR) Pseudomonas aeruginosa identified in Lima, Peru co-expressing a VIM-2 metallo-β-lactamase, OXA-1 β-lactamase and GES-1 extended-spectrum β-lactamase.

Authors:  Paul Ríos; Claudio Rocha; William Castro; Maria Vidal; Enrique Canal; Manuela Bernal; Nathanael D Reynolds; Drake H Tilley; Mark P Simons
Journal:  JMM Case Rep       Date:  2018-06-21

10.  In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-β-lactamase (VIM).

Authors:  Islam M Ghazi; Jared L Crandon; Emil P Lesho; Patrick McGann; David P Nicolau
Journal:  Heliyon       Date:  2016-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.